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Background: Decreases in endothelial function measured by reactive hyperemic index (RHI) correlated
with increases in carotid intima-media thickness (CIMT) in recently menopausal women with a low risk
cardiovascular proﬁle. Factors linking this association are unknown.
Objective: Assess, longitudinally, markers of platelet activation and cell-derived, blood-borne micro-
vesicles (MV) in relationship to RHI and CIMT in asymptomatic, low risk menopausal women.
Methods: RHI by digital pulse tonometry (n ¼ 93), CIMT by ultrasound (n ¼ 113), measures of platelet
activation and speciﬁc cell-derived, blood-borne MV were evaluated in women throughout the Kronos
Early Estrogen Prevention Study (KEEPS) at Mayo Clinic.
Results: CIMT, but not RHI, increased signiﬁcantly over 4 years. The average change in CIMT correlated
signiﬁcantly with the average follow-up values of MV positive for common leukocyte antigen [CD45;
r ¼ 0.285 (P ¼ 0.002)] and VCAM-1 [r ¼ 0.270 (P ¼ 0.0040)]. Using principal components analysis (PC) on
the aggregate set of average follow-up measures, the ﬁrst derived PC representing numbers of MV
positive for markers of vascular endothelium, inﬂammatory cells (leukocyte and monocytes), pro-
coagulant (tissue factor), and cell adhesion molecules (ICAM-1 and VCAM-1) associated with changes
in RHI and CIMT. Changes in RHI associated with another PC deﬁned by measures of platelet activation
(dense granular ATP secretion, surface expression of P-selectin and ﬁbrinogen receptors).
Conclusions: MV derived from activated endothelial and inﬂammatory cells, and those expressing cell
adhesion and pro-coagulant molecules may reﬂect early vascular dysfunction in low risk menopausal
women. Assays of MV as non-conventional measures to assess cardiovascular risk in asymptomatic
women remain to be developed.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vascular endothelial activation or dysfunction is a hallmark of
atherosclerotic processes [1,2]. Conventional cardiovascular risk
factors such as smoking, hypertension, dyslipidemia and elevated
blood glucose are factors contributing to chronic or over-activation, Rochester, MN 55905, USA.
iller).
Ireland Ltd. This is an open accessof the vascular endothelium. These factors collectively and syner-
gistically stimulate production of inﬂammatory cytokines, lipid
peroxidation, and oxidative stress which increase the adhesive
surface of the endothelium and decrease production of
endothelium-derived relaxing and anti-coagulant factors [3].
Working theories regarding progression of atherosclerosis
follow these processes and involve adhesion and activation of
platelets [4,5], activation and migration of inﬂammatory leuko-
cytes, particularly monocytes, into the vascular wall [6]. In addition
to secreting soluble vasoactive and mitogenic products, thesearticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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referred to in the earlier literature as microparticles) containing
bioactive material that varies with sex hormonal status [7e12]. MV
have been associated with endothelial dysfunction in patients with
pre-existing cardiovascular or renal disease [13e20]. However, MV
most likely are involved early in disease processes as the number of
thrombogenic MV and those of platelet origin correlated with
development (over a period of 4 years) of cerebral white matter
hyper-intensities in women enrolled in Kronos Early Estrogen
Prevention Study (KEEPS) [21]. The relationship of blood-borne MV
to endothelial function early in progression of vascular disease as
quantiﬁed by CIMT has not been examined in asymptomatic
women.
One non-invasive metric of endothelial function is pulse volume
digital tonometry which provides a measure of a reactive hyper-
emia index (RHI) [22]. In a cohort of non-smoking, low cardiovas-
cular risk, recently postmenopausal women enrolled in KEEPS, RHI
did not associate with conventional cardiovascular risk factors at
baseline [23] nor did changes in RHI vary among treatment groups
four years after randomization [24]. However, over the course of
four years in the overall cohort, decreased RHI (indicative of
endothelial dysfunction) associated with increased CIMT [24]. A
longitudinal assessment of measures of activated cells of the
vascular compartment, as might be provided by the number and
characteristics of speciﬁc cell-derived MV, may help to conﬁrm
mechanisms involved in the early stages of atherosclerotic pro-
cesses and may provide a set of additional measures that could be
used to assess cardiovascular risk in otherwise low risk persons.
Therefore, the purpose of this study was to determine the rela-
tionship, if any, between platelet and blood borne MVwith RHI as a
measure of endothelial function, and CIMT as a measure of early
atherosclerosis in asymptomatic but vulnerable (due to their
menopausal status) women. It was hypothesized that the number
and characteristics of blood-borne MVwould provide a generalized
assessment of early endothelial activation (dysfunction) leading to
peripheral vascular remodeling. Speciﬁcally, it was hypothesized
that the number of thrombogenic-, adhesive-, inﬂammatory- and
endothelium-derived MV would correlate negatively with RHI
(endothelial function) and positively with CIMT (early atheroscle-
rosis) in this asymptomatic cohort of recently menopausal women.
As neither changes in RHI nor CIMT were statistically different
among treatment groups [24,25], the analysis could address
mechanisms of vascular activation independent of hormonal status.
2. Methods
2.1. Participants
Study participants were recently menopausal women (42e59
years old, within 6 months to 3 years of their last menses) enrolled
in the Kronos Early Estrogen Prevention Study (KEEPS;
NCT00154180) at theMayo Clinic, Rochester, MN [26].Womenwere
excluded from KEEPS if they had a history of, or were symptomatic
for, cardiovascular disease; smoked more than ten cigarettes/day;
had coronary artery calciﬁcation (i.e., 50 Agatston Units), body
mass index >35 kg/m2, dyslipidemia (low-density lipoprotein
cholesterol >190 mg/dL), hypertriglyceridemia (triglycerides,
>400 mg/dL), 17b-estradiol >40 pg/mL; uncontrolled hypertension
(systolic blood pressure >150 mm Hg and/or diastolic blood pres-
sure >95 mm Hg) or fasting blood glucose >126 mg/dL [26,27]; or
used lipid lowering drugs. This study was approved by the Mayo
Clinic Institutional Review Board (IRB #2241-04 and #09-003464).
All participants gave written informed consent.
Each woman underwent a medical examination including body
mass index, waist-hip ratio measurements, standard bloodchemistries prior to (baseline) and during up to 4 years after
randomization to either oral conjugated equine estrogens (0.45mg/
day, oCEE), transdermal 17b estradiol (50 mg/day, tE2), each with
intermittent progesterone (200 mg/day for the ﬁrst 12 days of the
month), or placebo pills and patch (PL). Details regarding the
collection of blood for blood chemistries, measurement of CIMT by
B-mode ultrasound and digital tonometry as a measure of endo-
thelial function by RHI have been reported in detail previously
[23e25]. Mean coefﬁcient of variation of measures of CIMT at
baseline ranged from 0.0% to 7.7% [26].
2.2. Blood collection for platelet reactivity and blood-borne MV
Blood from an antecubital vein was collected from participants
after an overnight fast at baseline (prior to randomization to
treatment) and yearly after randomization for 4 years using a 19
gauge needle into tubes containing various anticoagulants: EDTA
(7.5% ethylenediaminetetraacetic acid tripotassium [EDTA (k3)]
salt) and 3.2% sodium citrate anticoagulants (calcium chelator an-
ticoagulants) for platelet count and platelet microaggregation; a
mixture of 1 mM hirudin (inhibits thrombin) plus 10 mM soybean
trypsin inhibitor (inhibitor for factor Xa) for the measurement of
dense-granular ATP secretion from platelets, basal expression of P-
selectin and ﬁbrinogen receptor (PAC-1) on the surface of platelets,
and markers of pro-coagulant and intravascular cellular adhesion,
and cellular-origin of blood-borne MV. To provide consistency and
to not activate the platelets, all samples were maintained at 33 C
until each test was performed within 30 min of collection.
2.3. Isolation, identiﬁcation, and characterization of blood-borne
MV by ﬂow cytometry
The detailed standardized method for the isolation, identiﬁca-
tion, separation, and quantiﬁcation of blood-borne MV (>0.2
micron) has been published by our group [9,10,28,29]. Brieﬂy,
platelet-free plasma was separated from whole blood by double
centrifugation at 3,000g for 15 min. Contamination of the plasma
by platelets and other cells was monitored by Coulter counter and
ﬂow cytometry. After validation, the platelet free plasma was
centrifuged at 20,000g for 30 min for MV isolation [29]. The pellets
of MV were washed and reconstituted with twice ﬁltered (0.2 mm
pore membrane ﬁlter) 20 mM HEPES/HANK’S buffer (pH 7.4) and
then vortexed for 1e2 min before staining with antibodies.
For identiﬁcation MV, digital ﬂow cytometry (FACSCanto™) was
used to deﬁneMV by size calibration beads and positive annexin-V-
ﬂuorescence [29]. Gates to deﬁne size are set using an internal
standard of 0.2, 0.5, 1, and 2 mm latex or silicon beads [29]. The
lowest detection limit for the digital ﬂow cytometer based on size
calibration beads is 0.2 microns [10,29]; therefore, MV detection
was set at this limit.
For quantiﬁcation, samples included a known quantity of beads
(TruCOUNT™) of 4.2 mm diameter. All antibodies were directly
conjugated with either ﬂuorescein isothiocyanate (FITC) or
phycoerythrin (PE). The FITC and PE conjugated rat anti-mouse IgG
and mouse anti-rabbit IgG isotype control antibodies were used as
controls and for threshold setting for ﬂuorescence dot or scatter
plot [29,30]. Our previous study veriﬁed the cellular origin of each
blood-borne MV using two different ﬂuorophores (FITC and PE)
conjugated to two distinct antibodies considered to be speciﬁc for
each cell type [7]. MVwere separated by ﬂuorescence scatter or dot
plot quadrants derived MV gate of light scatter plot in the presence
PE (Q1þQ2) and FITC (Q4þQ2) or absence of both (Q3) of staining
[7,10,29]. The absolute numbers of ﬂuorophores positive MV was
calculated based on counts of calibration beads. The absolute count
of speciﬁc ﬂuorophore positive MV ¼ number of counts in each
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bead region x number of beads per test (spiked known count)/test
volume [29]. The same calculation applied to quantitation of MV
positive or negative for annexin-V and each cell membrane speciﬁc
antibody. The calculated absolute number of MV from the two cell
surface markers for each cell type was similar (r2 ¼ 0.97) in same
person [7]. Numbers of isolated blood-borne MV from 0.2 to 1
microns are reported in this study. The intra-assay variability of MV
analysis is <10% [29].
2.4. Statistical analyses
Descriptive statistics were used to summarize the cohort,
including counts (percentages) for categorical variables and means
(SD, standard deviation) for continuous variables. In general, paired
differences were tested for a signiﬁcant change over time based on
the Wilcoxon signed rank test, and group differences in response
patterns were assessed using the KruskaleWallis test. To estimate
the strength of association between two continuous variables, the
nonparametric Spearman's rank correlation coefﬁcient was used.
Since previous ﬁndings revealed no signiﬁcant treatment effect on
the two study response variables of interest, RHI and CIMT, data for
these analyses were pooled across treatment groups. All analyses
were performed using the statistical programming language SAS,
version 9.3 (SAS Institute Inc., Cary, NC). An alpha level of 0.05 was
used to establish statistical signiﬁcance.
For serially collected responses RHI and CIMT, multiple mea-
surements per woman were reduced to a single measure of trend
by computing separately, for each woman, the change in their
average follow-up value from baseline, i.e. the difference between
their average follow-up value and their baseline value. This method
facilitated describing and analyzing trends and reduced the noise in
RHI measures which have shown high within-person variability
[24]. A similar approach was taken for summarizing the highly
variable serial measures of MV and platelet parameters, by using
the average over each participant's follow-up values. For each MV
and platelet parameter, the mean follow-up measure was then
correlated with the mean change of RHI and CIMT.
To assess the combined effects of the MV and platelet variables
on outcomes, while accounting for the varying degree of inter-
correlation and interaction among the 13 measured variables, we
used the statistical data reduction method known as principal
components analysis (PC). The objective of PC analysis is to attempt
to account for the joint variability in the 13 variables on the basis of
a smaller number of independent factors. Each factor, or PC, is
represented as a weighted linear combination of the original vari-
ables (a score), with statistical software computing the optimal
weights. The 1st PC is deﬁned as the linear combination that ac-
counts for the largest amount of variability in the data; succeeding
components are uncorrelated with the ﬁrst PC and with each other,
and account for progressively less variance. Having deﬁned these
principal components without regard to outcome data, each prin-
cipal component was then assessed for its association with the
outcome measures for RHI and CIMT using Spearman's correlation
analysis. This technique helps to reduce the problem of multiple
comparisons, while potentially increasing the signal to noise ratio
by combining multiple noisy measures into a smaller number of
independent variables.
3. Results
3.1. Clinical characteristics of participants
At Mayo Clinic, 118 Caucasian women enrolled in KEEPS; base-
line and at least one follow-up measure (either 1, 2, 3, or 4 years)were available from 93 women for RHI and from 114 women for
CIMT. Phenotypic and clinical characteristics of the Mayo cohort
have been reported previously [12,24], but are shown again in
Table 1. In general, baseline characteristics were similar across the
three treatment groups. At baseline, conventional risk factors for
cardiovascular disease (waist circumference, systolic blood pres-
sure, blood lipids, triglycerides, fasting blood glucose and C-reac-
tive protein) in the Mayo cohort were similar to those of the entire
KEEPS cohort [25] and place these women in a “low” (<5%) 10 year
risk category for cardiovascular disease as deﬁned by the Fra-
mingham Risk Score [23e25,27].
3.2. Longitudinal changes in RHI, CIMT, platelet parameters and
blood-borne MV
Measured on 93 participants, the mean (±SD) RHI was 2.40
(±0.69) at baseline and averaged 2.32 (±0.45) over available mea-
surements during follow-up (Fig. 1). Based on the paired difference
between each participant's average follow-up and baseline value,
there was no signiﬁcant mean change in RHI over the study period
(- 0.07 ± 0.61; P ¼ 0.211), nor was there a signiﬁcant difference in
these changes across treatment groups (P¼ 0.833). Consistent with
published results of the entire KEEPS cohort [25], CIMT increased
signiﬁcantly in the KEEPS participants at Mayo over the study
period (P < 0.001), and these changes did not differ statistically
across treatment groups (P ¼ 0.332). For 114 participants, CIMT
increased on average from 0.678 mm (±0.079) at baseline to 0.690
(±0.087) mm at follow-up, corresponding to an average increase of
0.012 mm (±0.028) over 4 years (Fig. 1). None of the baseline
clinical factors listed in Table 1 correlated signiﬁcantly with
changes in CIMT or in RHI [range of Spearman's correlation co-
efﬁcients, (0.12, 0.14)].
In general, there was high intra-individual variability in mea-
surements of platelet activation and the MV parameters during the
four years of follow-up. Examples of the longitudinal variability for
platelet-, endothelium- and monocyte-derived MV are shown in
Fig. 2.
3.3. Associations of activation of platelets and blood-borne MV with
RHI and CIMT
To account for the longitudinal, intra-individual variability in
each parameter, the average of each follow-up value for the
particular measure of platelet activation or cell-speciﬁc MV was
obtained for each woman and assessed for correlation with the
average change in RHI and CIMT (Table 2). Among those markers of
platelet activation and MV showing a nominally signiﬁcant result,
the average follow-up values for basal expression of ﬁbrinogen
receptors on platelets (P¼ 0.021) and monocyte-derived
(P¼ 0.023) MV were positively associated with the average
change in RHI (Table 2). In addition, the average follow-up levels of
both total leukocyte-derived MV (P¼ 0.002) and MV positive for
VCAM-1 (P¼ 0.004) showed positive associations with changes in
CIMT (Table 2; Fig. 3).
To account for the varying degree of inter-correlation and
interaction among the 13 measured variables for platelet and MV
parameters, principal components (PC) analysis was performed.
This analysis leads to a small number of independent dimensions
(or principal components) while retaining most of the original in-
formation. Using this approach, ﬁve principal components were
retained in the analysis, which altogether accounted for about 68%
of the information in the original data (Table 3). In testing the as-
sociation with each vascular outcome, two of the 5 independent
principal components (PC1 and PC3) correlated signiﬁcantly with
changes in RHI, while one of the ﬁve (PC1) correlated signiﬁcantly
Table 1
Summary of baseline characteristics.
Baseline variable Total (n ¼ 118) Placebo (n ¼ 43) tE2 (n ¼ 36) oCEE (n ¼ 39)
Age, years 53.1 ± 2.4 53.0 ± 2.4 53.1 ± 2.4 53.1 ± 2.4
Menopausal age (months) 19.2 ± 9.1 17.0 ± 9.0 20.9 ± 8.3 20.2 ± 9.7
Body mass index (kg/m2) 27.1 ± 4.2 27.1 ± 3.8 26.3 ± 4.2 27.7 ± 4.5
Waist circumference (cm) 84.3 ± 11.6 84.3 ± 11.8 83.2 ± 11.3 85.4 ± 12.0
Systolic blood pressure (mm Hg) 122.2 ± 14.0 122.2 ± 12.5 120.0 ± 16.1 124.2 ± 13.7
Diastolic blood pressure (mm Hg) 75.4 ± 8.0 75.3 ± 7.5 73.8 ± 8.7 77.0 ± 7.7
Fasting glucose (mg/dL) 80.1 ± 9.3 79.8 ± 7.1 81.8 ± 12.3 78.8 ± 8.1
Total cholesterol (mg/dL) 205.4 ± 31.6 200.8 ± 32.7 213.7 ± 30.4 202.9 ± 30.7
HDL cholesterol (mg/dL) 70.2 ± 13.3 69.2 ± 13.2 70.3 ± 11.4 71.1 ± 15.1
LDL cholesterol (mg/dL) 118.5 ± 28.1 116.3 ± 27.7 123.7 ± 31.8 116.1 ± 24.9
Triglycerides (mg/dL) 87.4 ± 47.1 84.1 ± 46.0 93.3 ± 42.5 85.6 ± 52.9
C-reactive protein (mg/L)a 1.5 (0.5, 3.0) 1.5 (0.5, 2.8) 1.6 (0.7, 2.8) 1.1 (0.4, 3.6)
a Median (25th and 75th percentile).
Fig. 1. Absolute values of RHI (left panel) and CIMT (right panel) during follow-up from the subset of women enrolled in KEEPS at Mayo Clinic that had been randomly assigned to
receive placebo (as there were no statistically signiﬁcant differences in these trends among treatment groups, presentation of data was limited to this subgroup for ease of
visualizing the trends). Each line connects serial measures from an individual, and the bolded curve estimates the overall group trend using a nonparametric loess smooth.
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cant associations. Based on the null distribution of p-values from 10
separate correlations tested, the expected number of type I errors
from these analyses is ~0.5, which is to say that on average, zero to
one associations detected as nominally signiﬁcant at the 0.05 level
would have occurred by chance alone. With a total of 3 such as-
sociations detected from the 10 essentially independent tests (i.e.,
well more than the expected chance ﬁnding of 0.5), it is unlikely
that chance alone explains the associations and more likely that at
least some of these ﬁndings were not type I errors.
The ﬁrst principal component (PC1) accounted for 24% of the
variability in these data, and included MV derived from endothelial
cells, leukocytes, andmonocytes and those positive for tissue factor,
and cellular adhesion molecules ICAM-1 and VCAM1 (bolded en-
tries in Table 3). The third principal component (PC3), which
accounted for 11% of the variance (that was not explained by the
ﬁrst two components), included measures of platelet activation,
speciﬁcally the secretion of ATP, basal expression of P-selectin and
ﬁbrinogen receptor with platelet count.4. Discussion
This study provides the ﬁrst longitudinal assessment of platelet
activation and speciﬁc cell-derived, blood borne MV reﬂecting a
measure of global activation of the cellular vascular compartment
in a cohort of asymptomatic recently menopausal women catego-
rized as “low risk” by conventional cardiovascular risk factors.
Speciﬁcally, a panel of MV parameters is identiﬁed that most likely
reﬂects early stages of disease processes. Although each conven-
tional cardiovascular risk factor was within normative ranges for
these women at entry into the study, variables such as blood
pressure, blood lipids and glucose, etc. are continuous variables the
collective and synergistic effects of which may activate the cellular
vascular compartment contributing to early stages and progression
of atherosclerosis as measured by CIMT. This conclusion is consis-
tent with previous studies demonstrating that individual compo-
nents of the metabolic syndrome (waist circumference, blood
pressure, blood glucose, triglycerides and high density lipopro-
teins) as well as the formulation of hormone treatments (oral
conjugated equine estrogens or transdermal 17b-estradiol) asso-
ciate with speciﬁc aspects of platelet activation in vitro [12,31,32]
Fig. 2. Measures of platelet- (left panel), endothelium- (middle panel) and monocyte- (right panel) derived MV from the subset of women enrolled in KEEPS at Mayo Clinic that had
been randomly assigned to receive placebo (as there were no statistically signiﬁcant differences in these trends among treatment groups, presentation of data was limited to this
subgroup for ease of visualizing the trends). Each line tracks values over time for an individual and the bolded curve estimates the overall group trend using a nonparametric loess
smooth.
Table 2
Correlation of average follow-up value of blood platelet reactivity and blood-borne MV with average change in vascular reactivity (RHI) and
structure (CIMT).a
Parameter Avg change in RHIc
N ¼ 93
Spearman r
Avg change in CIMTb
N ¼ 114
Spearman r
Platelets and measures of activation
Platelet count 0.157 0.064
Platelet microaggregates 0.097 0.038
ATP secretion 0.077 0.019
Basal expression of P-selectin 0.097 0.054
Basal expression of ﬁbrinogen receptor 0.240* 0.095
Cellular origin of microvesicles (MV)
Endothelium (CD62E)-derived MV 0.090 0.055
Leukocyte (CD45)-derived MV 0.068 0.285**
Monocyte (CD14)-derived MV 0.236* 0.104
Platelet (CD42a)-derived MV 0.032 0.107
Thrombogenic microvesicles
Phosphatidylserine positive MV 0.008 0.164
Tissue factor positive MV 0.047 0.021
Microvesicles expressing adhesion molecules
ICAM-1 positive MV 0.194 0.107
VCAM-1 positive MV 0.162 0.270**
Note: Spearman's r rank correlation coefﬁcient for measuring the association between summary measure and response (*P < 0.05, **P < 0.01).
a Abbreviations: RHI, reactive hyperemic index; CIMT, carotid intima-media thickness.
b A signiﬁcant change in CIMT was detected using the average (Avg) change since baseline (p < 0.001).
c There was no signiﬁcant change in RHI based on average change (p ¼ 0.211).
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In addition, the association of markers of immunological, in-
ﬂammatory and pro-coagulant functions with CIMT is consistent
with the working theories regarding contributions of platelets,
leukocytes, and immune competence to vascular disease processes
[33,34]. These observations are also consistent with the identiﬁed
genetic variants within the innate immunity pathways and the
pharmacogenomic interactions of treatment with those genetic
variants that associated with increases in CIMT in the KEEPS cohort
[35,36].
Global assessment of immune and thrombogenic activation
identiﬁed by the MV shown to associate with CIMT in the presentstudy may help to stratify cardiovascular risk for recently meno-
pausal women. It must be cautioned that these associations were
identiﬁed in a longitudinal analysis in which there was large bio-
logical variability in individual measures within each parameter
over the four years. However, it should be noted that the longitu-
dinal intra-individual variability in MV measures exceeded the
intra-assay variability [29]. Some biological variability in longitu-
dinal assessment of each parameter should be expected given the
short circulating half-life of platelets, the dynamic nature of the
interaction of various blood elements with sources of their stimu-
lation (i.e. changes in soluble proteins, glucose and lipids and
commensal and acute infection), and their interaction with each
Fig. 3. Relationships between the average change in CIMT with the average follow-up values for leukocyte-derived MV (left panel) and MV positive for VCAM-1 (right panel). Each
point represents an individual.
Table 3
Principal components (PC) analysis of the average change in platelet and MV parameters with the average change in RHI and CIMT.
Variable Average follow-up value
Loadings PC1 PC2 PC3 PC4 PC5
Platelets and measures of activation
Platelet count 0.03 0.17 ¡0.53 0.33 0.26
Platelet microaggregates 0.03 0.19 0.06 0.63 0.38
ATP secretion 0.02 0.04 0.38 0.59 0.44
Basal expression of P-selectin 0.06 0.21 0.52 0.07 0.01
Basal expression of ﬁbrinogen receptor 0.02 0.03 0.46 0.19 0.67
Cellular origin of microvesicles (MV)
Endothelium (CD62-E)-derived MV 0.44 0.13 0.06 0.03 0.11
Leukocyte (CD45)-derived MV 0.38 0.22 0.18 0.12 0.03
Monocyte (CD14)-derived MV 0.44 0.06 0.13 0.18 0.01
Platelet (CD42a)-derived MV 0.13 0.63 0.06 0.15 0.14
Thrombogenic microvesicles
Phosphatidylserine positive MV 0.13 0.64 0.01 0.11 0.07
Tissue factor positive MV 0.32 0.05 0.11 0.12 0.30
Microvesicles expressing adhesion molecules
ICAM-1 positive MV 0.43 0.12 0.08 0.01 0.00
VCAM-1 positive MV 0.37 0.05 0.15 0.03 0.15
Proportion of variance 24% 16% 11% 10% 8%
Cumulative proportion 24% 40% 50% 60% 68%
Spearman's r rank correlation with
Change in RHI 0.211a 0.046 0.237a 0.026 0.119
Change in CIMT 0.199a 0.071 0.118 0.053 0.051
Bolded values represent the variables with the strongest loadings on each of the 5 PCs.
Abbreviations: RHI, reactive hyperemic index; CIMT, carotid intima-media thickness; MV, microvesicles.
a Denotes a signiﬁcant correlation between PC and outcome measure (P < 0.05).
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variability raises a caution for the development of both diagnostic
and prognostic “biomarkers” of cardiovascular disease measured at
a single time point. Development of a panel of MV from different
cell types as provided by the PC analysis, rather than assessment of
single MV alone, may provide a better risk assessment for cardio-
vascular disease at a single time point. However such panels would
need to be developed and validated in larger and more diverse
groups of women than those represented by KEEPS.
One unexpected ﬁnding of the present study was the positive
correlation of PC1 components with RHI. It was hypothesized that
increases in inﬂammatory processes would correlate with de-
creases rather than increases in the RHI. However, the RHI repre-
sents the response to mechanical shear stress across the surface ofthe endothelial cells as well as the autonomic tone of resistance
arteries. RHI associated with the PC reﬂecting platelet activation
which seems to be consistent with shorter-term, reactive functions
of platelets. The average decreases in RHI did associate with in-
creases in CIMT [24] thus, perhaps reﬂecting, chronic cellecell
activation and interactions. In the future, MV reﬂecting endothelial
activation should be investigated following arterial vasodilatation
in response to intra-arterial injection of acetylcholine.
The KEEPS cohort provides an ideal study population for
investigation of mechanisms involved in the early stages of vascular
remodeling as the inclusion criteria for KEEPS were rigorous. First,
vascular structure quantiﬁed by CIMTand computed tomography of
coronary arterial calciﬁcation prior to enrollment indicated that
these women were without clinical classiﬁcation of cardiovascular
V.M. Miller et al. / Atherosclerosis 246 (2016) 21e28 27disease. In addition, all conventional cardiovascular risk factors
were deﬁned within clinically normative ranges [26]. Finally, the
lower doses and formulations of hormonal treatments used in
KEEPS did not signiﬁcantly affect either changes in CIMT or RHI
[24,25]. It should be noted that, in spite of signiﬁcant hormonal
effects on speciﬁc platelet functions [12,32], the rate of change in
CIMT observed in KEEPS is comparable to that reported in other
studies [37]. The absence a hormonal effect most likely reﬂects the
“low risk” status of the participants [37], doses of hormones used in
the study [38,39] and signiﬁcant pharmacogenomics interactions
[36].
A limitation of the current study is that the MV were quantiﬁed
without measurement of percentage of MV associated with other
intravascular cells at the time of the blood collection. Evaluating the
MV association with other cells by use of dual or triple marker
identiﬁcation (e.g., MV carrying a combination of platelet, leuko-
cyte, adhesion molecule, and thrombogenic signals) may reduce
individual variability in the data and provide a better indication of
the interaction among the cells in the blood with the vascular wall.
In summary, results of this study provide evidence that in
women categorized as “low risk” by conventional cardiovascular
risk assessment tools, markers of cellular activation, inﬂammation
and pro-coagulant properties associate positively with increases in
CIMT. These markers may reﬂect the synergistic activity of con-
ventional cardiovascular risk factors that are on a continuumwithin
normative ranges. Markers of platelet activation in conjunction
with MV reﬂecting activation of cells involved with thrombogenic
and inﬂammatory responses suggest that a more global assessment
of activation of the vascular compartment may add value to
establishing cardiovascular risk stratiﬁcation for women.
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